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A B S T R A C T
New discoveries providing insights into mitochondrial bioenergetics, their dynamic interactions as well as their
role in cellular homeostasis have dramatically advanced our understanding of the neurodegenerative process of
Parkinson’s disease (PD). Respiratory chain impairment is a key feature in sporadic PD patients and there is
growing evidence that links proteins encoded by PD-associated genes to disturbances in mitochondrial function.
Against the backdrop of latest advances in the development of PD treatments that target mitochondria, we aim to
give an overview of the literature published in the last three decades on the significance of mitochondria in the
pathogenesis of PD. We describe the contribution of mitochondrial genome alterations and PD-associated genes
to mitochondrial maintenance. We highlight mitophagy as a key mechanism in neurodegeneration. Moreover,
we focus on the reciprocal interaction between alpha-synuclein aggregation and mitochondrial dysfunction. We
discuss a novel trafficking pathway involving mitochondrial-derived vesicles within the context of PD and
provide a synopsis of the most recently emerging topics in PD research with respect to mitochondria. This
includes the relationship between mitochondria and cell-mediated immunity, the ER-mitochondria axis, sirtuin-
mediated mitochondrial stress response and the role of micro RNAs in the aetiology of PD. In addition, recent
studies have challenged the neuro-centric view of PD pathology, moving microglia and astrocytes into the re-
search spotlight. Greater insights into these mechanisms may hold the key for the development of novel targeted
therapies, addressing the need for a disease-modifying treatment, which has remained elusive to date.
1. Introduction
Mitochondria are known to play key roles in cellular signalling
processes using the cell’s bioenergetics status to determine whether the
cell survives or undergoes degeneration. As such, mitochondria have a
fundamental role in the neurodegenerative process of Parkinson’s dis-
ease (PD), the most common neurodegenerative movement disorder in
the world. PD affects about 1% of people over the age of 60 years (de
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Lau and Breteler, 2006; Mehta et al., 2007) and is characterised by
cardinal motor manifestations of bradykinesia, tremor, rigidity and
postural instability, as well as non-motor features. Pathological findings
include loss of dopaminergic neurons in the substantia nigra (SN) pars
compacta and the intraneuronal presence of Lewy bodies. Lewy bodies
contain aggregates of alpha-synuclein, neurofilaments, ubiquitin, and
other compounds (Spillantini et al., 1997).
Although most cases of PD are sporadic, about 5–10% of affected
patients have a monogenic form of the disease with Mendelian in-
heritance (Deng et al., 2018; Kumar et al., 2011, 2012a).
Major insights from recent genetic discoveries have underpinned the
importance of mitochondria in the neurodegenerative process of PD, as
multiple genes unequivocally linked to the disease encode proteins that
are relevant for mitochondrial homeostasis. Among this subset are the
presynaptic protein alpha-synuclein, the E3 ubiquitin ligase Parkin,
PTEN-induced putative kinase 1 (PINK1), the protein deglycase DJ-1,
Leucine-rich repeat kinase 2 (LRRK2), ATPase 13A2 (ATP13A2) and
vacuolar protein sorting-associated protein 35 (VPS35) (Larsen et al.,
2018). In the following, we will highlight the relationship between the
afore-mentioned proteins and mitochondria in the context of (ac-
celerated) neurodegeneration and PD.
2. Respiratory chain complex dysfunction as a key feature of PD
2.1. Respiratory impairment in IPD
Mitochondria initially became the focus of PD research when Drs
Langston, Ballard, Tetrud and Irwin from California reported two in-
cidents of drug abuse in an article published in Science in 1983
(Langston et al., 1983). Within a week of exposure, four patients
showed typical signs of L-dopa-responsive Parkinsonism after injecting
what they believed to be a new “synthetic heroin”. The compound that
was injected intravenously contained the mitochondrial toxin 1-Methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Langston et al. linked
their findings to an earlier case report (Davis et al., 1979), which de-
scribed the onset of similar symptoms in a 23-year old student who had
injected a “sloppy batch” of self-synthesized 1-methyl-4-phenyl-4pro-
pionoxy-piperine (MPPP). Autopsy material of this patient revealed
typical Lewy body pathology in the SN (Davis et al., 1979).
MPTP can pass the blood brain barrier and is converted into the
cation 1-methyl-4-phenylpyridinium (MPP+) by monoamine oxidase B
- an enzyme highly abundant in glial cells (Levitt et al., 1982). Via the
dopamine transporter (DAT), MPP+ selectively enters dopaminergic
neurons (Storch et al., 2004) where it inhibits respiratory chain com-
plexes I, III and IV (Desai et al., 1996; Nicklas et al., 1985). The as-
sumption that PD can be triggered by mitochondrial impairment was
corroborated when, 6 years later, reduced activities of complexes I, II
and IV were determined in post-mortem SN homogenates of PD patients
(Bindoff et al., 1989; Schapira et al., 1990a,b, 1989). These publications
initiated vigorous research endeavours worldwide exploring the con-
tribution of mitochondria to the pathology of PD. Entering the search
terms “mitochondria” and “Parkinson’s disease” into the literature da-
tabase PubMed retrieved more than 2500 articles linked to the topic. In
comparison, “lysosomes” or “lysosome” and “Parkinson’s disease” only
linked about 500 publications over a similar timeframe.
Because of its effects on the respiratory chain, which results in a loss
of bioenergetic function, oxidative stress and impaired calcium home-
ostasis (Desai et al., 1996; Langston, 2017), MPTP is now considered
the “gold standard” for modelling PD in animals (Francardo, 2018;
Jackson-Lewis et al., 2012). Like in the above-described patient, MPTP
mediates the preferential degeneration of SN dopaminergic neurons in
mice and non-human primates, causing motor symptoms in the latter
model. By contrast, the occurrence of Lewy bodies, the neuropatholo-
gical hallmark of PD, in these animals is inconsistent (Dauer and
Przedborski, 2003). Due to this limitation, paraquat and rotenone are
used as alternatives to induce parkinsonian phenotypes in animals.
While paraquat ingestion generates reactive oxygen species (ROS) by
redox cycling, rotenone’s primary site of action is respiratory chain
complex I. Contrary to MPTP, both pesticides cause alpha-synuclein
aggregation and Lewy body-like inclusions but less reliably reproduce
the PD-associated loss of dopamine in the nigrostriatal pathway
(Jackson-Lewis et al., 2012).
The quest for a prodromal disease marker and an accurate cellular
system, which allowed studying the molecular causes of PD, motivated
the analysis of more accessible peripheral patient tissues. Enzyme ki-
netic analysis in mitochondria isolated from platelets (Benecke et al.,
1993; Krige et al., 1992; Parker et al., 1989) and skeletal muscle
(Bindoff et al., 1991; Cardellach et al., 1993) confirmed reduced com-
plex I and IV activity as a more widespread phenomenon in IPD. The
first two reports in which IPD patient fibroblasts were used to explore
mitochondrial function in vitro also described a complex I phenotype
(Mytilineou et al., 1994; Winkler-Stuck et al., 2004) (Table 1). In a
subset of patient-derived cultures, treatment with the antioxidant
coenzyme Q10 was sufficient to reverse the complex I deficit (Winkler-
Stuck et al., 2004) (Table 1). In line with a key role for complex I in IPD,
oxygen consumption profiles determined with an extracellular flux
analyser showed reduced rotenone-sensitive respiration (Ambrosi et al.,
2014). In contrast, a study comprising the largest collection of IPD
patient (n=20) and control (n=19) fibroblasts to date showed no
abnormalities for complexes IeIV, only a mild (but significant) reduc-
tion in the activity of complex V (Table 1) (del Hoyo et al., 2010). A
comparison of the average disease durations in the studied cohorts
(Mytilineou et al.: n/a; Winkler-Stuck et al.: 4.2+/−3.1 years; Ambrosi
et al.: 12.1+/−6.0 years; and del Hoyo et al.: 8.1+/4.2 years) did not
explain this discrepancy. Given that none of the patients had mutations
in PD-associated genes excluded, it is possible that the observed
variability is (at least in part) due to genetic heterogeneity. An attempt
to define homogeneous subpopulations of sporadic patients by strati-
fication according to valinomycin sensitivity did not result in distinct
respiratory chain complex phenotypes between the two groups. How-
ever, in the “high sensitivity” IPD group, fewer mitochondrial-lyso-
somal co-localization events were found together with increased nitric
oxide and mitochondrial superoxide generation (Smith et al., 2016).
Primary or toxin-induced respiratory chain complex dysfunction in
PD is tightly interlinked with the generation of ROS. ROS develop when
electrons prematurely escape from the electron transport chain. The
main sites for such events are located at respiratory chain complexes I
and III (Quinlan et al., 2013). In addition, mitochondria possess a
specific nitric oxide synthase which catalyses nitric oxide formation
from L-arginine and O2 (Nisoli and Carruba, 2006). Reactive nitrogen
species (RNS) are produced via the interaction of superoxide with nitric
oxide (Al Shahrani et al., 2017). ROS and RNS are important for normal
cellular physiology and their intracellular levels are regulated by anti-
oxidants such as superoxide dismutase (SOD) and glutathione (GSH)
(Puspita et al., 2017). In PD, this equilibrium was shown to be disturbed
(Bosco et al., 2006) with the exact cause still being elusive. However,
multiple lines of evidence suggest that mitochondrial oxidative stress is
mediated by dopamine metabolism (Blesa et al., 2015). Dopamine can
undergo auto-oxidation producing free radicals and active quinones
(LaVoie and Hastings, 1999) which interact with ROS scavengers
(Belluzzi et al., 2012; Jana et al., 2007), respiratory chain complexes
(Jana et al., 2007) or proteins of the mitophagy pathway (LaVoie et al.,
2005). A study using induced pluripotent stem cell (iPSC)-derived
neurons from human and mice with mutant or depleted DJ-1 demon-
strated a species-specific relationship between dopamine oxidation
mitochondrial dysfunction and lysosomal dysfunction in PD (Burbulla
et al., 2017). Given that DJ-1 functions in ROS defence, neurons lacking
DJ-1 may serve as model of primary mitochondrial oxidative stress
(Guzman et al., 2010). The experiments revealed a pathogenic cascade
from mitochondrial via lysosomal to neuronal dysfunction, which was
exacerbated in the presence of high cytosolic dopamine levels. It was
postulated that higher dopamine concentrations resulted in the
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Table 1
Endogenous mitochondrial function studies in PD patient fibroblasts.
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(Mytilineou et al., 1994) 4 6 Not sequenced B
(Winkler-Stuck et al., 2004) 15 18 Not sequenced B B Coenzyme Q10
(Hoepken et al., 2008) 5 5 Not sequenced B
(del Hoyo et al., 2010) 19 20 Not sequenced B B
(Ambrosi et al., 2014) 7 11 Not sequenced B B/S B/S S
(Smith et al., 2016) 14 10 No mutations in LRRK2 or GBA1 S B/S B/S B/S S B/S LRRK2-in-1  (LRRK2 kinase 
inhibitor)
(Hsieh et al., 2016) 4 5 No mutations in known PD genes S
nikraP
(Mortiboys et al., 2008) 6 5
c.255delA/delEx5; c.202-
203delAG/c.202-203delAG; c.202-
203delAG/delEx2; c.202-
203delAG/delEx4; c.202-
203delAG/c.1289G>A
B/S B KD
(Rothfuss et al., 2009) 1 1 c.101delAG/delEx3-4 B/S
(Grunewald et al., 2010) 5 6
c.1072delT/delEx7; 
c.1072delT/1072delT; delEx7/delEx7; 
delEx3-4/duplEx7-12; c.924C>T/delEx4; 
c.924C>T/delEx1
B/S B/S S
(Pacelli et al., 2011) 1 2 delEx2-3/delEx3 B/S B B B B
(Rakovic et al., 2011a) 2 2 c.1072delT/c.1072delT; delEx7/delEx7 S S OE
(Mortiboys et al., 2013) 4 4
c.255delA/delEx5; c.202-
203delAG/c.202-203delAG; c.202-
203delAG/delEx2; c.202-
203delAG/delEx4
B B
Ursocholanic acid, 
dehydro(11,12) ursolic 
acid, ursolic acid, urso-
deoxycholic acid lactone 
(activators of 
glucocorticoid receptor, 
GR)
(Ferretta et al., 2014) 1 2 delEx2-3/delEx3; delEx7-9/c.1326G>T B/S B B B B/S B KD
(van der Merwe et al., 2014) 2 3 delEx3-4/delEx3-4; delEx4/delEx4 (n=2) B B B
(Zanellati et al., 2015) 4 4
c.815C>G/c.924C>T; c.202-
203delAG/c.202-203delAG; 
delEx1/c.924C>T; duplEx2/delEx3-5
B/S B B
(Gautier et al., 2016) 8 7
delEx1-2/c.202-203delAG; delEx8-
9/c.226G>C (n=3); delEx4/c.255delA; del 
ex3-6/delEx3-4; delEx5/c.1422T>C
B
OE
(Parkin)/KD
(MFN2)
(Hsieh et al., 2016) 4 3 delEx3-4/c.255delA; 
c.226G>C/c.226G>C; c.924C>T/c.924C>T
B S
(Haylett et al., 2016) 3 3 delEx3-4/delEx3-4; delEx4/delEx4 (n=2) B/S B
(Lobasso et al., 2017) 2 2 delEx7-9/c.1326G>T; delEx2-3/delEx3 B
(Zanon et al., 2017) 2 2 c.1072delT/c.1072delT; 
delEx7/c.1072delT
S
nikraP (h
et
) (Ferretta et al., 2014) 1 1 delEx2-3* B/S B B B B/S B
(van der Merwe et al., 2014) 2 2 delEx2-3*; delEx4* B B B
PI
N
K1
(Hoepken et al., 2007) 2 3 c.926G>A/c.926G>A (n=3) B B
(Piccoli et al., 2008b) 1 1 c.1311G>A/c.1311G>A B/S B B B
Dyphenylene iodinium 
(nitric oxide synthetase 
inhibitor)
(Piccoli et al., 2008a) 1 1 c.1311G>A/c.1311G>A B B B
(Hoepken et al., 2008) 5 3 c.926G>A/c.926G>A (n=3) B KD
(Grunewald et al., 2009) 8 5 c.1366C>T/c.1366C>T (n=4); 
c.509T>G/c.509T>G
B B/S B B/S
(Klinkenberg et al., 2010) 4 3 c.926G>A/c.926G>A (n=3) B/S KD
(Rakovic et al., 2010) 4 4 c.1366C>T/c.1366C>T (n=3); 
c.509T>G/c.509T>G
S OE (Parkin)
(Rakovic et al., 2011a) 2 2 c.1366C>T/c.1366C>T; 
c.509T>G/c.509T>G
S S OE
(continued on next page)
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increased vulnerability of human neurons when compared to mouse
nigral neurons (Burbulla et al., 2017). Notably, administration of in-
organic nitrite can disrupt this vicious circle in various animal and
cellular models of PD. In the presence of nitrate, the antioxidant Nrf2
pathway is activated and S-nitrosation of complex I is favoured over
other types of oxidation which leads to improved mitochondrial effi-
ciency and neuroprotection (Milanese et al., 2018)
While iPSC-derived neurons from genetic PD patients are widely
used to explore the cellular pathways that underlie mitochondrial
dysfunction, oxidative stress and neurodegeneration, the potential of
iPSC technology for research into IPD has not been fully exploited yet.
Contrary to all previous IPD models, iPSC-derived neurons enable
analyses against the biological environment of the original patient
genotype. To date, there are no reports that comprehensively study the
involvement of respiratory chain deficiency in the pathogenesis of IPD
using iPSC-derived patient neurons (Table 2). Additional studies em-
ploying iPSC technology may be beneficial for elucidating further me-
chanistic insights into this condition.
2.2. PD-associated proteins with links to the respiratory chain
In 1997, the first gene mutation underlying a familial form of PD
was discovered. In three Greek kindreds, Polymeropoulos and co-au-
thors identified the Ala53Thr substitution in the alpha-synuclein pro-
tein (Polymeropoulos et al., 1997) - known now to be a component of
the Lewy body (Spillantini et al., 1997). Another report of a German
family harbouring an Ala30Pro mutation in alpha-synuclein (Kruger
et al., 1998) swiftly followed. Overexpression of Ala30Pro alpha-sy-
nuclein in PC12 cells brought the first evidence of a mitochondrial
contribution in familial PD. Compared to wild-type, mutant lines
showed significantly increased mitochondrial depolarization (Tanaka
et al., 2001). Remaining doubts as to the significance of mitochondria
in the pathogenesis of PD were subsequently dispelled when PINK1, the
protein encoded by the PARK6 gene, was located in the mitochondria of
transfected COS-7 cells (Valente et al., 2004).
Among the proteins unequivocally linked to familial forms of PD,
PINK1 remains the best example with the strongest evidence for a direct
Table 1 (continued)
Notes: Controls screened for mutations in respective PD gene highlighted in bold. Number of isogenic control or mutant samples in brackets. Shading:
Green - normal function, grey - altered function, blue - successful rescue, red - failed rescue attempt. Abbreviations: B - under basal conditions; KD -
knockdown; OE - overexpression; S - under stress conditions; *Cells from unaffected individuals.
(Abramov et al., 2011; Azkona et al., 2018; Di Nottia et al., 2017; Ferretta et al., 2014; Grunewald et al., 2010; Grunewald et al., 2014a; Haylett et al.,
2016; Hoepken et al., 2007; Hoepken et al., 2008; Klinkenberg et al., 2010; Lobasso et al., 2017; Mortiboys et al., 2008; Mortiboys et al., 2010; Mortiboys
et al., 2013; Pacelli et al., 2011; Papkovskaia et al., 2012; Piccoli et al., 2008a; Piccoli et al., 2008b; Rakovic et al., 2011b; Su and Qi, 2013; van der Merwe
et al., 2014; Vos et al., 2017; Verma et al., 2017; Wang et al., 2016; Wang et al., 2017; Zanellati et al., 2015).
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Table 2
Endogenous mitochondrial function studies in iPSC-derived PD patient neurons.
Notes: Controls screened for mutations in respective PD gene highlighted in bold. Number of isogenic control or mutant samples in brackets. Shading:
Green - normal function, grey - altered function, blue - successful rescue, red - failed rescue attempt. Abbreviations: B - under basal conditions; KD -
knockdown; OE - overexpression; S - under stress conditions; §study performed in neuroepithelial stem cells, *cells from unaffected individual; #isogenic
mutant; $study performed in sensory neurons.
(Chung et al., 2016; Cooper et al., 2012; Imaizumi et al., 2012; Schwab and Ebert, 2015; Sanders et al., 2014; Sanchez-Danes et al., 2012; Schwab and
Ebert, 2015; Shiba-Fukushima et al., 2017; Suzuki et al., 2017; Reinhardt et al., 2013).
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interaction with the mitochondrial respiratory chain. PINK1-knockout
mice show a loss of phosphorylation at serine 250 of the complex I
subunit NdufA10 in brain tissue (Morais et al., 2014). Phosphorylation
at this site is a prerequisite for ubiquinone reduction. Overexpression of
a phosphomimetic version of NdufA10 was sufficient to rescue re-
spiratory chain function in PINK1-knockout mouse embryonic fibro-
blasts or pink1-null mutant drosophila (Morais et al., 2014). By con-
trast, NdufA10 overexpression in parkin-null mutant flies failed to
rescue mitochondrial morphology and locomotor phenotypes im-
plicating that PINK1 acts on complex I via a mechanism independent of
mitophagy (Pogson et al., 2014). Such mechanisms may involve the
drosophila homolog of UBIAD. UBIAD/Heix is a modifier of the pink1-
null phenotype and mediates the conversion of vitamin K1 into vitamin
K2 (Vos et al., 2012). Feeding pink1-null flies with vitamin K2 sup-
plemented media was sufficient to improve cellular ATP levels and
mitochondrial membrane potential (Vos et al., 2012).
Regarding human endogenous models, respiratory chain dysfunc-
tion is the most frequently identified mitochondrial phenotype in fi-
broblasts from patients with PINK1 mutations (Table 1). For example,
analysis of the 3D structure of complex I revealed a shift from free to
supercomplex-assembled complex I and complex III and an overall
depletion of complex IV in skin cells from PINK1 patients (Lopez-Fabuel
et al., 2017). These changes have implications for mitochondrial bioe-
nergetics and ROS production (Lopez-Fabuel et al., 2016).
Although the above-described results from drosophila studies may
give the impression that Parkin’s impact on the respiratory chain is only
via the PINK1/Parkin mitophagy pathway, the protein’s actions in hu-
mans are manifold. Applying co-immunoprecipitation and proximity
ligation assays to SH-SY5Y cells, Parkin was demonstrated to interact
with mitochondrial Stomatin-like protein 2 (SLP-2), which is required
for the assembly of respiratory chain proteins (Zanon et al., 2017). The
significance of this finding was emphasised when overexpression of
SLP-2 successfully recovered complex I deficiency in iPSC-derived pa-
tient neurons with Parkin mutations (Zanon et al., 2017). The mole-
cular theme of impaired respiratory chain complex assembly in genetic
PD also extends to DJ-1 (Heo et al., 2012) and VPS35 (Zhou et al.,
2017). In DJ-1-knockout mouse neurons and VPS35-mutant patient fi-
broblasts, abnormal complex I formation was observed using blue-na-
tive PAGE (Heo et al., 2012; Zhou et al., 2017) (Fig. 1).
3. Mitochondrial genome involvement in PD
3.1. Inherited and somatic mtDNA variation in IPD
Evidence for a role of maternally inherited mitochondrial DNA
(mtDNA) alterations in the pathogenesis of IPD was provided by studies
employing transmitochondrial cytoplasmic hybrids (or “cybrids”). To
generate cybrids, control cells with “wild-type” nuclear background are
deprived of their own mtDNA by incubation with ethidium bromide.
The resulting Rho° cells are then fused with cytoplasts or enucleated
cells derived from patient cells only containing the patient mtDNA
(Taylor and Turnbull, 2005). Rather than using enucleated cells, Parker
et al. (Parker et al., 1989) and Krige et al. (Krige et al., 1992) used
anucleate platelets from IPD patients as an ideal source of mtDNA for
such transmission experiments (Gu et al., 1998; Swerdlow et al., 1996).
Cybrids obtained in this fashion were more susceptible to MPP+and
recapitulated the original complex I defects, indicating that mtDNA
from affected patients contributed to the aetiology of IPD (Gu et al.,
1998; Swerdlow et al., 1996) (Fig. 1). In contrast, a study investigating
the association between maternal transmission and risk of PD in 168
affected families failed to demonstrate a maternal bias in the in-
heritance of the disease. Moreover, common mtDNA haplogroups or the
mitochondrial 10,398 G variant located in the ND3 subunit of complex I
did not define the risk to develop PD (Mehta et al., 2009; Simon et al.,
2010), thus challenging previous, presumably underpowered reports,
ascribing a higher disease risk to the mitochondrial haplotype groups J
(van der Walt et al., 2003), K (Ghezzi et al., 2005; van der Walt et al.,
2003), UK (Khusnutdinova et al., 2008) or UKJT (Pyle et al., 2005).
Despite increasing sample numbers and, therefore, enhancing power
(Hudson et al., 2013), the significance of mtDNA association analyses
remains limited due to a lack of studies which underpin the genetic
results on a cellular level (Giannoccaro et al., 2017). To date, only two
Fig. 1. Respiratory chain dysfunction and
mtDNA alterations in Parkinson’s disease (PD).
Respiratory chain dysfunction primarily invol-
ving complexes I and IV are often identified in
idiopathic PD. As a consequence of impaired
oxidative phosphorylation, the cellular levels
of reactive oxygen (ROS) and nitrogen species
(RNS) rise. This initiates a viscous cycle, which
is exacerbated in the presence of dopamine.
Toxins such as MPTP, paraquat (PQ) and ro-
tenone can mirror the clinical phenotypes of
idiopathic PD by inhibiting complex I or
through the generation of ROS and RNS.
Oxidative stress and replication errors occur-
ring during ageing and PD are the cause of
major arc deletion in the mitochondrial
genome (mtDNA). Clonal expansion of these
deleted mtDNA molecules results in a complex
IV deficit. While, in aging, the accumulation of
deleted species is compensated by an increase
in copy number, in IPD, the level of wild-type
mtDNA molecules recedes. This coincides with
an impairment of mitochondrial transcription
and replication. Regarding PD-associated pro-
teins, mutations in the ROS scavenger DJ-1
enhance mitochondrial oxidative stress, which
acts on complex I. Similarly, mutant forms of PINK1, VPS35, alpha-synuclein and Parkin interfere with complex I function. The interplay between mitochondrial
dysfunction and alpha-synuclein is bidirectional, i.e. respiratory chain impairment can also induce alpha-synuclein accumulation and aggregation. Furthermore,
Parkin can either modulate mtDNA transcription via ubiquitination of the PGC-1α repressor Paris (in the cytosol) or via direct interaction with TFAM at the
mitochondrial genome. Fig. 1 was created using elements from Servier Medical Art, which is licensed under a Creative Common Attribution 3.0 Generic License
(http://smart.servier.com/).
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reports have used cybrid technology to uncover differences in mtDNA
copy number, transcription, protein synthesis, and respiratory chain
function between haplogroups UK, J and H (Giannoccaro et al., 2017;
Gomez-Duran et al., 2010, 2012).
In any case, considering that ageing is the strongest factor influen-
cing PD risk, somatic mutations are likely to outweigh the effect of
mtDNA polymorphisms over time (Giannoccaro et al., 2017). In
agreement with this hypothesis, Alper’s disease patients, who accu-
mulate somatic mtDNA mutations throughout life due to an error-prone
version of polymerase gamma (POLG), show more severe neuronal loss
in the SN than patients with inherited mtDNA mutations (Reeve et al.,
2013). The most common mtDNA change occurring during ageing is a
4977bp deletion in the mitochondrial genome (Soong et al., 1992). This
large deletion is especially abundant in brain regions with high dopa-
mine metabolism and auto-oxidation, such as the caudate, putamen and
the SN (Soong et al., 1992). A combination of immunohistochemistry,
laser capture microdissection and single-neuron (Bender et al., 2006) or
single-molecule (Kraytsberg et al., 2006) mtDNA analysis of SN sections
from aged individuals revealed that cytochrome c oxidase (COX)-ne-
gative dopaminergic neurons harbour higher deletion levels than those
with normal activity. This phenomenon was even more pronounced in
IPD patients (Bender et al., 2006), providing a first molecular ex-
planation for the long-established respiratory phenotype in IPD (Fig. 1).
When single-cell technology was applied to non-catecholaminergic and
catecholaminergic nigral neurons with or without neuromelanin,
highest deletion levels were found in pigmented tyrosine hydroxylase
(TH)-positive cells highlighting their specific vulnerability (Elstner
et al., 2011). By contrast, more recent research shows that respiratory
chain dysfunction in IPD does not exclusively stem from sporadically
formed and clonally expanded large-scale mtDNA deletions (Nido et al.,
2018). In an attempt to explore the contribution of the mitochondrial
genome to complex I rather than complex IV deficiency, we substituted
COX/succinate dehydrogenase (SDH) histochemistry as mitochondrial
function readout by quantitative immunofluorescence labelling of var-
ious respiratory chain subunits (Grunewald et al., 2014b). Surprisingly,
complex I abundance in pigmented SN neurons from IPD patients was
not determined by the extent of deletion accumulation but by the
number of mtDNA copies per cell (Grunewald et al., 2016). Implicating
mito-nuclear signalling in IPD, neuronal complex I levels tightly cor-
related with the abundance of mitochondrial transcription factor A
(TFAM). In concordance with impaired mtDNA maintenance in dopa-
minergic patient neurons, triplex real-time PCR analysis indicated
fewer mtDNA molecules with associated 7S DNA strands (Grunewald
et al., 2016), which are required for the initiation of mitochondrial
transcription and replication (Nicholls and Minczuk, 2014). Finally,
besides complex I, mtDNA, TFAM, and TFB2M depletion, we detected a
slight but significant reduction in the abundance of the entirely nuclear-
encoded respiratory chain complex II in patient neurons (Grunewald
et al., 2016). This result additionally emphasized that a disturbance in
the communication between nucleus and mitochondria is part of the
complex landscape of PD pathology (Fig. 1). In two studies from the
Tzoulis laboratory, the relationship between mtDNA major arc dele-
tions, copy number and respiratory chain deficiency in ageing and IPD
was further examined. While in SN neurons of healthy aged individuals
the occurrence of major arc mtDNA deletions coincided with an in-
crease in copy number thereby maintaining a constant pool of wild-type
mtDNA molecules, this compensatory mechanism was not present in
IPD patients (Dolle et al., 2016). Moreover, the dependence of complex
I on mtDNA copy number is restricted to the SN, albeit IPD patient
neurons in the prefrontal cortex, the hippocampus and putamen also
show a significant loss of complex I (Flones et al., 2018). This finding
could indicate that (i) very subtle changes in mtDNA (deletion) levels
below the current detection limit are sufficient to cause a significant
impact on complex I; (ii) disturbances in the regulation of nuclear genes
coding for respiratory chain subunits precede mtDNA disintegration, or
that (iii) complex I dysfunction and mtDNA disintegration are the result
of two distinct processes, i.e. impaired mitophagy and dopamine-in-
duced oxidative stress, respectively. To disentangle these three sce-
narios, patient-derived cellular models may be useful despite their
limitations (Kang et al., 2016). By contrast, we could not identify a
single publication employing fibroblasts or, more sensibly, post-mitotic
iPSC-derived dopaminergic neurons from sporadic patients with a focus
on mtDNA involvement in IPD (Tables 1 and 2).
3.2. PD-associated proteins involved in mtDNA maintenance
Regarding PD-associated proteins, Parkin has the strongest links to
mtDNA maintenance. Firstly, via the degradation of PARIS, a repressor
of PPARGC1A expression, Parkin regulates the peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC-1α)-mediated
transcription of nuclear genes encoding for e.g. TFAM, TFB2M and the
majority of complex subunits (Shin et al., 2011). Secondly, chromatin
immunoprecipitation and co-immunoprecipitation studies suggest a
direct interaction between Parkin and TFAM at the mtDNA D-loop
(Kuroda et al., 2006; Rothfuss et al., 2009). In SH-SY5Y cells (Rothfuss
et al., 2009) and mouse cortical neurons (Zheng et al., 2017), over-
expression of wild-type Parkin enhanced mtDNA transcription and re-
plication. By contrast, in patient fibroblasts with Parkin mutations,
mtDNA transcription is severely suppressed (Rothfuss et al., 2009).
Supporting these in vitro studies, mutator Parkin-knockout mice, which
combine parkin depletion with POLG proofreading deficiency, showed
enhanced loss of TH-positive SN neurons. The concomitant lack of
dopamine caused motor phenotypes, which were reversible by L-DOPA
(Pickrell et al., 2015). Furthermore, knocking-out parkin in the genetic
mutator background accelerated the accumulation of pathogenic
mtDNA mutations in these animals (Pickrell et al., 2015). In line with
these findings, crossing PD-mito-PstI mice, which express mitochon-
drial-targeted endonuclease PstI under control of a DAT promotor
leading to dopaminergic neuron-specific mtDNA depletion (Pickrell
et al., 2011), with Parkin-knockout mice accelerated the neurodegen-
erative phenotype and precipitated the onset of motor symptoms (Pinto
et al., 2018). Interestingly, the lack of Parkin in the resulting animals
caused a rise in mtDNA copy number, which was not associated with an
increase in mitochondrial mass or clearance (Pinto et al., 2018). This
further highlights the possibility of a role for Parkin in mtDNA main-
tenance independent from mitophagy (see Section 5 for details on
Parkin’s involvement in mitophagy).
Apart from the above-mentioned study in endogenous Parkin-mu-
tant cells, mtDNA integrity data in fibroblasts and neurons from genetic
PD patients are sparse or, as in case of Parkin and LRRK2, inconsistent
(Tables 1 and 2). Conversely, the only two publications, which assessed
mtDNA features in neurons with Parkin mutations, did not detected
differences between patient and control cultures (Jiang et al., 2011;
Shaltouki et al., 2015).
4. Impact of alpha-synuclein aggregation on mitochondrial
function: a reciprocal interaction
4.1. Alpha-synuclein interferes with mitochondrial function
The mechanism by which alpha-synuclein accumulation contributes
to the death of dopaminergic neurons in PD is currently unclear, but
there is growing evidence that mitochondrial dysfunction may play a
role. Alpha-synuclein has been shown to accumulate in mitochondria
thereby impairing various functions of the organelles (Chinta et al.,
2010; Devi et al., 2008). The N-terminal domain of alpha-synuclein is
important for mitochondrial targeting where it may be associated with
complex I (Devi et al., 2008) (Fig. 1). Disruption of this N-terminal
domain results in elongation of mitochondria, implicating alpha-synu-
clein in the maintenance of mitochondrial size (Pozo Devoto et al.,
2017). Further data supporting a link between alpha-synuclein and
respiratory chain dysfunction was collected in endogenous PD models
A. Grünewald et al. Progress in Neurobiology 177 (2019) 73–93
79
(Table 2). A technique known as ‘FACS-assisted CRISPR-Cas9 editing’
was used to generate isogenic lines of PD-associated mutations (Arias-
Fuenzalida et al., 2017). In alpha-synuclein p.A53T-mutant neuroe-
pithelial stem cells, the maximal respiration capacity was reduced.
Additionally, both the p.A30 P and p.A53 T mutation in alpha-synuclein
lowered the energy performance as demonstrated by a reduction in
basal, ATP-linked and non-mitochondrial respiration (Arias-Fuenzalida
et al., 2017).
In addition, a disease mechanism involving toxic species of wild-
type alpha-synuclein was identified by Di Maio and colleagues (Di Maio
et al., 2016). Alpha-synuclein has the ability to assemble into fibrils
thereby accepting amyloid-like structures as present in Lewy bodies
(Crowther et al., 1998). During this conformational change, alpha-sy-
nuclein transitions from monomers to mature fibrils via protofibrillar
oligomers. These short elongated oligomers are composed of more than
15 monomers and it has been reported that these aggregates can spread
from cell to cell in a prion-like fashion (Luk et al., 2012). While
monomeric and fibrillar forms of the protein do not interact, oligomeric
and dopamine-modified forms of alpha-synuclein can bind to the
TOM20 (translocase of outer membrane 20) receptor of the mitochon-
drial protein import machinery (Di Maio et al., 2016). As a result of this
interaction, TOM20 can no longer bind to its co-receptor TOM22, re-
sulting in impaired mitochondrial protein import. The consequences of
this include reduced mitochondrial respiration with increased produc-
tion of ROS and a loss of mitochondrial membrane potential. Notably,
this process was confirmed in nigrostriatal neurons from post-mortem
brains of individuals with IPD (Di Maio et al., 2016). Nigrostrial neu-
rons are particularly vulnerable because they are long, feature nu-
merous synapses (Bolam and Pissadaki, 2012; Surmeier et al., 2017)
and have high energy requirements to match the elevated electrical
excitability, thereby resulting in increased levels of mitochondrial oxi-
dative stress (Faustini et al., 2017; Surmeier et al., 2017).
Oxidative stress and apoptosis may be of particular importance in
the relationship between alpha-synuclein and mitochondria. In both
SH-SY5Y cells and isolated rat brain mitochondria, cytochrome c re-
lease is caused by an interaction between alpha-synuclein and mi-
tochondria, and is associated with an increase of mitochondrial calcium
and nitric oxide, and oxidative modification of mitochondrial compo-
nents (Parihar et al., 2008). More recently, synthetic human preformed
alpha-synuclein fibrils (PFFs) were shown to induce respiratory chain
impairment, oxidative stress, and inflammation in rat ventral midbrain
dopamine neurons (Tapias et al., 2017). Interestingly, when the in-
vestigators blocked the expression of inducible nitric oxide synthase
(iNOS), a reduction in protein nitration levels and protection against
PFFs-induced dopaminergic neuron death was detected, indicating a
role for iNOS-derived nitrogen oxide in the pathogenicity of PFFs.
Further evidence for mitochondrial dysfunction occurring sec-
ondary to alpha-synuclein pathology comes from MPTP models of PD.
In alpha-synuclein A30P transgenic mice, MPTP treatment led to en-
hanced degeneration of the nigrostriatal dopaminergic system when
compared to non-transgenic controls (Nieto et al., 2006). This suggests
that overexpression of A30P-mutant alpha-synuclein enhances the
neuronal susceptibility to MPTP. In keeping with this concept, mice that
are deficient of alpha-synuclein have been shown to be more resistant
to the effects of MPTP on dopaminergic neurons (Dauer et al., 2002).
These findings have been confirmed in MPTP-treated SH-SY5Y cells.
Suppression of alpha-synuclein reduced the transport of dopamine in
human cells, thereby altering dopamine homeostasis and increasing
cellular survival in the presence of MPTP (Fountaine and Wade-Martins,
2007).
Controversially, there is also data in the literature that suggests a
neuro-protective role for alpha-synuclein (Sidhu et al., 2004). Mice
lacking alpha-synuclein have altered mitochondrial membrane com-
position and structure as well as complex I/III defects in the brain (Ellis
et al., 2005). Furthermore, unfolded, monomeric alpha-synuclein was
shown to interact with ATP synthase subunit alpha to improve ATP
synthase efficiency in mice. Alpha-synuclein deficiency increased re-
spiration and caused lower mitochondrial membrane potential and ATP
levels (Ludtmann et al., 2016). Alpha-synuclein may also be required
for endoplasmic reticulum (ER)-mitochondrial signalling. The impact of
mutations in alpha-synuclein on mitochondria-associated endoplasmic
reticulum membrane (MAM) function is summarized in Section 7.2
below.
4.2. Mitochondrial dysfunction mediates alpha-synuclein accumulation
Evidence in support of the hypothesis that mitochondrial dysfunc-
tion precedes alpha-synuclein accumulation comes from studies ex-
ploring the role of pesticides such as paraquat and rotenone in the
pathogenesis of PD. Exposure of rodent models to these agents led to an
increase in alpha-synuclein aggregation (Nistico et al., 2011; Tieu,
2011). By contrast, paraquat and rotenone neither directly interact with
alpha-synuclein nor alter fibrillation of the protein (Maturana et al.,
2015). This implies that the observed alpha-synuclein phenotype in
these animal models occurs downstream of mitochondrial impairment.
Similarly, chronic administration of MPTP increased the number of
alpha-synuclein-positive nigral neurons in mice (Vila et al., 2000).
Further data in support of alpha-synuclein accumulation as an event
occurring secondary to mitochondrial dysfunction was collected in
studies of genetic PD. Mutations in ATP13A2 cause a complicated form
of autosomal recessive PD (Kufor Rakeb syndrome) (Ramirez et al.,
2006). ATP13A2 codes for a lysosomal type 5 P-type ATPase which is
believed to function as a cation pump (Park et al., 2014). In fibroblasts
from patients with Kufor Rakeb syndrome, altered respiratory chain
function, increased mtDNA copy numbers and deletion levels have been
reported (Grunewald et al., 2012) (Table 1). Moreover, in patient-de-
rived human olfactory neurosphere cultures, zinc dyshomeostasis due
to mutations in ATP13A2 was shown to provoke mitochondrial depo-
larization, fragmentation, ATP depletion, and cell death (Park et al.,
2014). ATP13A2 mutations also cause lysosomal dysfunction in patient-
derived fibroblasts, reduced proteolytic processing of lysosomal en-
zymes, decreased degradation of the substrates of lysosomes, and di-
minished clearance of autophagosomes by lysosomes (Dehay et al.,
2012) (Table 1). In this context, ATP13A2 has been shown to localize to
multi-vesicular bodies (MVBs), which can serve as a link between the
autophagic and endosomal pathways. MVBs may function as exosomes
to release intracellular cargoes including zinc and alpha-synuclein
(Kong et al., 2014). While ATP13A2 overexpression reduced in-
tracellular alpha-synuclein levels due to enhanced exocytosis, this
exosomal release of alpha-synuclein was compromised in ATP13A2-
deficient cells (Kong et al., 2014). Given that, ATP13A2 depletion was
previously associated with impaired bioenergetics (Grunewald et al.,
2012; Park et al., 2014), these experiments place mitochondrial dys-
function upstream of intracellular alpha-synuclein accumulation.
Taken together, these studies suggest that the relationship between
alpha-synuclein and the mitochondria is reciprocated and tightly
regulated. Disturbances in the dynamics of this interaction may result in
a shift of the properties of alpha-synuclein from neuro-protective to
neuro-toxic.
5. Mitochondrial homeostasis: mitophagy maintains
mitochondrial function
5.1. PINK1/Parkin-mediated mitophagy selectively degrades damaged
mitochondria
Mitochondrial homeostasis is dependent on the continued turnover
of mitochondria to maintain their optimal function. Key to the main-
tenance of mitochondrial health is the process of “mitophagy” or the
selective degradation of mitochondria via autophagy (Gao et al., 2017;
Lemasters, 2005). There are several forms of autophagy including mi-
croautophagy and endosomal microautophagy, chaperone-mediated
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autophagy and macroautophagy (Galluzzi et al., 2017; Gao et al.,
2017). Mitophagy is a well-characterised form of a macroautophagy
that occurs in mammalian cells (Galluzzi et al., 2017). Important PD-
related genes have been shown to play pivotal roles in the process of
mitophagy.
PINK1/Parkin-mediated mitophagy is the most investigated me-
chanism for the homeostatic quality control of mitochondria. PINK1
senses mitochondrial depolarisation, ROS, or protein misfolding
(Shirihai et al., 2015) (Fig. 2) and triggers mitophagy. The mitochon-
drial-targeting sequence of PINK1 guides the protein to the mitochon-
dria. Under basal conditions, PINK1 is rapidly degraded as its trans-
membrane domain enters the translocase of outer membrane (TOM)/
translocase of inner membrane (TIM) complex and is cleaved by pre-
senilins-associated rhomboid-like protein (PARL) (Harper et al., 2018).
The degradation of PINK1 after import is disrupted when mitochondria
become depolarised, leading to a build-up of PINK1 and the recruitment
of the E3 ubiquitin ligase Parkin (Gao et al., 2017). There are differing
views on the how Parkin is translocated from the cytosol (Shirihai et al.,
2015). By contrast, it has been confirmed that the PINK1-mediated
phosphorylation of Ser65 in the ubiquitin-like domain stabilizes and
activates Parkin at the mitochondria (Harper et al., 2018). This is
highlighted by a study showing that the recruitment of Parkin to mi-
tochondria is dependent upon PINK1 expression, and that the over-
expression of wild-type but not mutant forms of PINK1 causes
relocation of Parkin to mitochondria (Vives-Bauza et al., 2010). Parkin
ubiquitinates various outer mitochondrial membrane proteins including
Mitofusin1/2 (MFN1/2) and voltage-dependent anion-selective channel
1 (VDAC1) (Karbowski and Youle, 2011). In turn, the resulting poly-
ubiquitin chains are phosphorylated by PINK1 (Fig. 2). These damage
signals recruit ubiquitin-binding autophagy receptors such as p62 (se-
questosome 1) and optineurin (OPTN) to the mitochondria. Finally, the
depolarized organelles are engulfed by LC3-positive phagophores (the
precursors to autophagosomes) and eventually degraded by lysosomal
hydrolases (Harper et al., 2018).
The PINK1/Parkin mitophagy pathway has been confirmed in PD
patient-derived fibroblasts (Rakovic et al., 2011a, 2010) and iPSC-de-
rived neurons (Rakovic et al., 2013; Seibler et al., 2011) (Tables 1 and
2). Fibroblasts from individuals with PINK1 mutations were used to
show that PINK1 regulates the stress-induced decrease in endogenous
Parkin as well as the translocation of Parkin, that endogenous PINK1 is
stabilised on mitochondria that are depolarised, and that mitochondrial
accumulation of PINK1 is sufficient but not a prerequisite for the loss of
Parkin signal and Parkin mitochondrial translocation induced by stress
(Rakovic et al., 2010). Thus, primary human dermal fibroblasts origi-
nating from PD patients with various PINK1 mutations were used to
show the requirement of introducing an environmental factor such as
stress to detect the differences in the interaction of PINK1 and Parkin in
mutants compared to controls (Rakovic et al., 2010). PD patient-
Fig. 2. Mitophagy and mitochondrial-derived vesicle formation in Parkinson’s disease (PD). PINK1 is targeted to the mitochondria, where its transmembrane domain
enters the TOM/TIM complex and undergoes cleavage mediated by PARL. When mitochondria are uncoupled under the impact of oxidative stress, the processing of
PINK1 is prohibited, causing the protein to accumulate at the outer mitochondrial membrane. Here, PINK1 activates the E3 ubiquitin ligase Parkin, which ubi-
quitinates outer mitochondrial membrane proteins e.g. mitofusins and TOM. PINK1 stabilizes Parkin at the mitochondria by phosphorylation of Ser65 in the
ubiquitin-like domain, which promotes ubiquitin chain assembly. Moreover, ubiquitin itself can be phosphorylated by PINK1 on Ser65. Jointly, these events at the
outer mitochondrial membrane activate mitophagy receptors, which promote sequestration of mitochondria by autophagosomes. Additionally, ERK signalling can
regulate mitophagy. DJ-1 can activate ERK2 independently of the PINK1/Parkin pathway. To facilitate clearance of damaged mitochondria, Miro is removed from the
outer mitochondrial membrane thereby disrupting the connection with Milton and kinesin heavy chain (KHC, not shown). Mitochondria are attached via Milton and
KHC to the microtubule during mitochondrial transport. Mutations in LRRK2 can delay the removal of the PINK1/Parkin target Miro. Consequently, in the presence
of mutant LRRK2, mitochondrial arrest and the initiation of mitophagy is stalled. PINK1 and Parkin are also involved in the formation of mitochondrial-derived
vesicles, which serve to remove small-scale damaged cargo from the mitochondria. The current working hypothesis assumes that contact with oxidized proteins will
alter the lipid composition and change the curvature of the inner mitochondrial membrane. When the capacity of chaperones to counteract misfolding is reached,
mitochondrial proteins, including PINK1, can no longer be imported. Under these circumstances, Parkin is stabilized and activated at the mitochondria by PINK1-
mediated phosphorylation. Parkin-mediated ubiquitination of targets at the outer mitochondrial membrane is a requisite for the formation of vesicles, which travel to
the lysosome for degradation. Fig. 2 was partially adapted from a publication by Sugiura and colleagues (Sugiura et al., 2014) and elements from Servier Medical Art
(http://smart.servier.com/) were used.
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derived fibroblasts were also used to show that PINK1 and Parkin
mutations impair ubiquitination of Mitofusins (Rakovic et al., 2011a). A
study compared human primary fibroblasts and iPSC-derived neurons
from controls and PINK1 mutation carriers. The investigators demon-
strated that mitophagy differs between human non-neuronal versus
neuronal cells, and between “endogenous” cellular models in compar-
ison to models using Parkin overexpression (Rakovic et al., 2013).
Another study used iPSC-derived neurons from individuals with PD and
PINK1 mutations to demonstrate evidence of impaired recruitment of
Parkin to mitochondria, increased mitochondrial copy number, and
upregulation of PGC-1α (Seibler et al., 2011). These changes could be
corrected via lentiviral expression of wild-type PINK1, using a patient-
derived, biologically relevant cell model.
PINK1 and Parkin, both also play a role in mitochondrial home-
ostasis through their effect on mitochondrial fission and fusion
(Gao et al., 2017). PINK1 inhibits the fusion of damaged mitochondria,
which may serve the purpose of preventing contamination of healthy
mitochondria by those that are damaged (Shirihai et al., 2015). Ex-
cessive fission can be countered by the mitochondrial fusion proteins
MFN2 and protein optic atrophy 1 (OPA1) or by a dominant negative
mutation of the Drp1 fission protein (Giannoccaro et al., 2017).
5.2. Mutations in DJ-1 may contribute to impaired mitophagy
Mutations in DJ-1 are a rare cause of autosomal recessive PD
(Bonifati et al., 2003). A study investigated the mechanisms underlying
DJ-1-associated PD by using knockout mice and human carriers of DJ-1
mutations (Krebiehl et al., 2010). DJ-1 depletion led to disturbed mi-
tochondrial respiration, an increase in ROS, decreased mitochondrial
membrane potential and altered mitochondrial morphology. Further-
more, the basal autophagic degradation was reduced and there was an
accumulation of defective mitochondria in DJ-1-knockout cells coin-
ciding with a decrease in phospho-activated ERK2 (Fig. 2). The ERK1/2
pathway has been identified as an alternative regulator of mitophagy
(Hirota et al., 2015). This suggests that DJ-1 loss results in impaired
autophagy and an accumulation of dysfunctional mitochondria
(Krebiehl et al., 2010) (Table 1). Interestingly, DJ-1 can regulate ERK
signalling in parallel to the PINK1/Parkin mitophagy pathway. The
mitochondria-protective effects of DJ-1 are independent of PINK1 and
size exclusion chromatography revealed that the three proteins do not
complex together (Thomas et al., 2011).
5.3. Potential role of LRRK2 in mitophagy
Mutations in LRRK2 are a cause of autosomal dominant PD (Paisan-
Ruiz et al., 2004; Zimprich et al., 2004). LRRK2, a member of the
leucine-rich kinase family, has also been reported to have a role in
mitophagy. Overall, the common G2019S mutation in LRRK2 is the
most intensively studied mutation in iPSC-derived neurons regarding
mitochondrial function (Table 2). A study using human iPSC-derived
neurons showed that LRRK2 promotes the removal of Miro by forming a
complex with this protein (Hsieh et al., 2016) (Table 2). Miro is an
outer mitochondrial membrane protein, which serves to anchor mi-
tochondria to microtubule motors. Miro is removed to prevent mi-
tochondrial motility in the early stages of clearing dysfunctional mi-
tochondria and has been previously linked with PINK1 and Parkin (Liu
et al., 2012; Wang et al., 2011) (Fig. 2). Hsieh and colleagues showed
that the G2019S mutation in LRRK2 delays the arrest of dysfunctional
mitochondria and slows the initiation of mitophagy. In iPSC-derived
sensory neurons from PD patients, the G2019S mutation led to in-
creased levels of the autophagy markers p62 and LC3 (Schwab et al.,
2017). Moreover, sensory neurons showed neurite aggregations and
abnormal calcium dynamics. Theses defects were distinct from changes
observed in dopaminergic neurons (see Section 7.3 for details on a
study by the same group on dopaminergic neurons with G2019S mu-
tation) and may explain some of the non-motor symptoms in LRRK2-
associated PD (Schwab et al., 2017).
6. Mitochondrial quality control via mitochondrial-derived
vesicles (MDVs)
6.1. PINK1 and Parkin are required for MDV transport
MDVs are a trafficking pathway generated through the selective
incorporation of protein cargo, which is targeted to the late endosome/
multivesicular body, or to a subpopulation of peroxisomes (Neuspiel
et al., 2008; Soubannier et al., 2012a; Sugiura et al., 2014). MDVs are
stimulated by mitochondrial stress and the identification of their cargo
is dependent upon the nature of the mitochondrial stress (Soubannier
et al., 2012b). In particular, stress-induced MDVs are enriched for
oxidised proteins, suggesting they have a role in mitochondrial quality
control (Soubannier et al., 2012b).
It has been shown that Parkin and PINK1 are involved in the vesi-
cular trafficking pathway (McLelland et al., 2014). Following oxidative
stress, wild-type but not mutant Parkin promotes the biogenesis of
MDVs, which bud off from the mitochondria and contain specific cargo
proteins. The MDVs are dependent upon the expression of PINK1, and
eventually will target lysosomes for degradation. An interruption to this
parkin or PINK1-dependent pathway may affect the ability of mi-
tochondria to clear oxidised proteins, potentially adding to the mi-
tochondrial dysfunction seen in PD (McLelland et al., 2014) (Fig. 2).
Sugiura and colleagues have formulated a 4-step hypothesis to ex-
plain the mechanism of MDV generation by PINK1 and Parkin (Sugiura
et al., 2014). In ‘Step 1’, ROS or failure of proteins to assemble results in
an aggregation of unfolded, oxidised proteins within the matrix. Cardi-
olipin oxidation creates phosphatidic acid, which modulates the curva-
ture of the membrane. In ‘Step 2’, chaperones are saturated by protein
aggregates. This leads to a ‘very localised failure’ of importation at an
individual channel. The channels are also affected by local oxidation of
cardiolipin. For ‘Step 3’, phosphorylation of ubiquitin as well as the
ubiquitin-like domain of Parkin by PINK1 leads to the recruitment of
activated Parkin. This ubiquitination activity of Parkin facilitates the
creation of MDVs. Finally, in ‘Step 4’, an MDV is formed and released.
Regardless of the exact mechanisms responsible for the generation
of MDVs, it is clear that PINK1 and Parkin are involved (Sugiura et al.,
2014). This suggests that PINK1 and Parkin have dual roles in mito-
phagy and trafficking/degradation of specific oxidised cargo from mi-
tochondria (Sugiura et al., 2014) (Fig. 2).
6.2. Vesicle transport to peroxisomes
The purpose of vesicle delivery to the peroxisomes is unclear and
the only protein known to traffic to peroxisomes is MAPL (Braschi et al.,
2009; Mohanty and McBride, 2013). It has been shown that the ret-
romer complex, which is involved in transporting cargo from the en-
dosome to the Golgi apparatus, is a regulator of the transport of MAPL
from mitochondria to peroxisomes (Braschi et al., 2010). VPS35 and
VPS26 are in complex with MAPL and silencing of VPS35 or VPS26A
results in diminished delivery of MAPL to peroxisomes. VPS35 is re-
cruited to mitochondrial vesicles, and notably, mutations in VPS35 can
cause autosomal dominant PD (Kumar et al., 2012b; Vilarino-Guell
et al., 2011; Zimprich et al., 2011), underpinning the role of the ret-
romer complex in the aetiology of PD.
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7. Newly emerging roles for mitochondria in the pathogenesis of
PD
7.1. Mitochondria and cell-mediated immunity
Recent research shows that by regulating MDV formation, PINK1
and Parkin may also link PD to the immune system (Matheoud et al.,
2016). While PINK1 and Parkin are required for the budding of ROS-
induced MDVs from the mitochondria (McLelland et al., 2014), they
repress the generation of heat-shock and liposaccharide-induced MDVs
thereby preventing mitochondrial antigen presentation (MitAP)
(Matheoud et al., 2016). Under inflammatory conditions, MitAP is in-
duced by the recruitment of the cytosolic proteins Rab9 and Snx9 to the
mitochondria. Once MDVs have been formed, the GTPase Rab7 likely
enables their fusion with late endosomes where the mitochondrial an-
tigens are enzymatically processed (Matheoud et al., 2016). Before
being mounted onto and displayed by major histocompatibility com-
plex I (MHC-I) molecules, the peptides are proteolytically cleaved in the
cytosol and finally trimmed to 8–10 amino acids-long fragments in the
ER. The presence of mitochondrial antigens at the cell surface may then
activate specific cytotoxic T cells (Lazaro et al., 2015). This process is
kept in check by the PINK1/Parkin pathway. Stress-induced transloca-
tion of Parkin to the mitochondria ensures that the mitochondrial
concentration of Snx9 is regulated in a proteasome-dependent manner
(Matheoud et al., 2016). It is important to note that while the pre-
sentation of exogenous antigens on MHC II molecules can only be
performed by specialized immune cells, the MHC I pathway for en-
dogenous peptide presentation exists in all nucleated cells, including
dopaminergic neurons (Cebrian et al., 2014; Matheoud et al., 2016). In
the absence of Parkin, the activation of MitAP may trigger a response by
cytotoxic T cells, which eventually causes neuronal demise. MHC I
presentation in dopaminergic neurons may alternatively be induced by
cytokine release from microglia that have been activated by neurome-
lanin or alpha-synuclein. The latter protein has been shown to elicit an
immune response in mice (Benner et al., 2008; Theodore et al., 2008).
By contrast, MHC II-deficient mice are protected against neuronal death
due to alpha-synuclein overexpression (Harms et al., 2013). In PD pa-
tients, peptides from two different regions within alpha-synuclein
produce a response by CD4+ or CD8+T cells. These are the Y39 an-
tigenic region, which is situated in close proximity to known alpha-
synuclein point mutations, and the S129 antigenic region, which re-
quires phosphorylation as typically found in Lewy bodies (Sulzer et al.,
2017). Finally, mitochondrial stress provoked by a partial depletion of
TFAM can cause the mtDNA to escape from mitochondria into the cy-
tosol where it engages innate immune signalling in mouse embryonic
fibroblasts (West et al., 2015). Taken together, these studies suggest
that the mitochondrial, mtDNA maintenance and lysosomal disease
mechanisms in PD may converge at the level of cell-mediated im-
munity.
7.2. Links between astrocyte and neuronal mitochondrial dysfunction in PD
Research into the role of alpha-synuclein in glial cells is not limited
to the above-described studies in microglia. In a recent series of pub-
lications by the Erlandsson lab, uptake, degradation and toxicity of
oligomeric alpha-synuclein were tested in a co-culture system of mouse
primary neurons, astrocytes and oligodendrocytes (Lindstrom et al.,
2017). Astrocytes were shown to engulf alpha-synuclein from the ex-
tracellular space and to degrade the protein via the lysosomal pathway.
However, at large alpha-synuclein concentrations, the digestion capa-
city of astrocytes was reached and intracellular deposits formed and
interfered with mitochondrial function (Lindstrom et al., 2017). In a
study using iPSC-derived human astrocytes, it was further demon-
strated that overburdened astrocytes connect with nearby healthy as-
trocytes via tunnelling nanotubes (TNTs). Through the TNTs, stressed
cells can release oligomeric alpha-synuclein and obtain functional
mitochondria in return. This intercellular rescue mechanism was
abolished by treatment with the F-actin depolymerization drug la-
trunculin B (Rostami et al., 2017). In another study from the same
group, the therapeutic effect of alpha-synuclein oligomer-selective an-
tibodies was tested in a murine co-culture system. Indeed, in the pre-
sence of these antibodies, extracellular alpha-synuclein was cleared
more efficiently and the intracellular digestion of the protein was en-
hanced. Moreover, previously observed mitochondrial phenotypes in
alpha-synuclein-ingesting astrocytes were reversed after treatment
(Gustafsson et al., 2017). However, astrocyte dysfunction in PD is not
exclusively linked to alpha-synuclein. Astrocytes cultivated from
Parkin-knockout mice exhibited an increased number of morphologi-
cally altered mitochondria and an upregulation of the mitochondrial
proteins PINK1, Drp1 and SOD2 upon oxidative stress (Schmidt et al.,
2011). Furthermore, in astrocytes derived from PINK1-knockout mice,
proliferation defects were associated with a decrease in mitochondrial
mass, membrane potential and ATP production as well as an increase in
cellular ROS. Treatment of wildtype astrocytes with the ATP synthase
inhibitor oligomycin was sufficient to mimic the proliferation pheno-
type observed in PINK1-deficient murine cells (Choi et al., 2013). It is
conceivable that impaired mitochondrial metabolism in astrocytes
constrains their neuron support function.
7.3. ER-mitochondria axis
Between 5 to 20% of the mitochondrial surface is situated opposite
of the ER. ER-mitochondria signalling is crucial for lipid biosynthesis,
inflammasome formation, cellular calcium handling and mitochondrial
homeostasis (Gomez-Suaga et al., 2018). Especially within the context
of the two latter functions, MAMs have been linked to PD. Character-
istics in their calcium handling properties, may explain the specific
vulnerability of nigral dopaminergic neurons in PD. A study from Sur-
meier’s laboratory found that these neurons heavily rely on L-type Ca
(v)1.3 Ca2+ channels for rhythmic pacemaking (Chan et al., 2007). This
dependency is age-associated as juvenile dopamine neurons in the SN
use pacemaking mechanisms similar to neuron types not affected by PD
(Chan et al., 2007). Considering these findings, it is conceivable that
even slight disturbances of ER-mitochondria contacts would have det-
rimental consequences for the survival of dopaminergic neurons
(Gomez-Suaga et al., 2018). One such interfering factor is alpha-synu-
clein, which was identified at the MAM in mouse and human brain
tissue. This association with the MAM is weakened by pathogenic
mutations in alpha-synuclein coinciding with fewer areas of ER-mi-
tochondria apposition, impaired MAM function and increased mi-
tochondrial fragmentation (Guardia-Laguarta et al., 2014). While
overexpression of wild-type alpha-synuclein successfully recovered the
mitochondrial morphology phenotype, rescue experiments with MFN2
and DRP1 had no impact on the mitochondrial network. These analyses
place alpha-synuclein downstream of the mitochondrial fusion and
fission machinery (Guardia-Laguarta et al., 2014). The connection be-
tween mitochondria and the ER is stabilized by tethering complexes. In
humans, this includes an interaction between the outer mitochondrial
membrane protein, protein tyrosine phosphatase-interacting protein 51
(PTPIP51) and the ER protein, vesicle-associated membrane protein-
associated protein B (VAPB) (Gomez-Suaga et al., 2018). Alpha-synu-
clein can bind to VAPB and overexpression of wild-type or mutant
forms of alpha-synuclein disrupts the VAPB-PTPIP51 tethers. This
finding could be recapitulated in iPSC-derived neurons from a PD pa-
tient with an alpha-synuclein triplication (Table 2). Loosening of the
mitochondria-ER contacts impairs calcium exchange between the two
organelles, which in turn lowers ATP production (Paillusson et al.,
2017). In addition to alpha-synuclein, also PINK1 and Parkin seem to be
required for ER-mitochondria cross talk (Gomez-Suaga et al., 2018).
Both proteins are targeted to MAMs upon mitochondrial depolarization,
where they recruit autophagy factors (Gelmetti et al., 2017; Yang and
Yang, 2013). Confocal and electron microscopy analyses showed closer
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interactions between ER and mitochondria in fibroblasts from patients
with mutations in Parkin than in control cells. Functionally, Parkin
mutations led to enhanced inter-organelle calcium transfer not only in
patient fibroblasts but also in thereof-derived patient neurons (Gautier
et al., 2016). The Parkin substrate MFN2, which forms mitochondria-ER
tethers with MFN1 (Gomez-Suaga et al., 2018), was considerably more
abundant in MAMs of Parkin-knockout than control mouse tissue.
Moreover, MFN downregulation and Parkin overexpression rescued the
calcium dyshomeostasis in Parkin-mutant patient fibroblasts. Finally,
also DJ-1 was found to modulate mitochondrial calcium transients via
its effect on ER-mitochondria coupling in HeLa cells. Even under p53-
induced stress, which causes reduced mitochondrial calcium buffering
capacity and ER-mitochondria contact sites, DJ-1 overexpression suf-
ficed to re-establish normal ER-mitochondria tethering (Ottolini et al.,
2013).
7.4. Sirtuin-mediated mitochondrial stress response
Sirtuin proteins are nicotinamide adenine dinucleotide-dependent
deacetylases, which mediate the cellular response to mitochondrial
stress. This includes the mitochondrial unfolded protein response
(UPRmt), ROS scavenging and events of mitochondrial maintenance
such as fusion, fission and mitophagy (Lin et al., 2018). Especially,
SIRT1 and SIRT3 have recently received much attention in PD research
with respect to the PINK1/Parkin mitophagy pathway. Genetic deple-
tion of SIRT1 led to diminished deacetylation and a decrease in activity
of the mitochondrial superoxide dismutase 2 (SOD) in mice. In turn,
higher ROS levels in SIRT1-knockout cells accelerated the mitochon-
drial translocation of Parkin (Di Sante et al., 2015). Given the distinct
cellular localization of SIRT1 (cytosolic) and SOD2 (mitochondrial) (Lin
et al., 2018), the authors of the respective study speculate that the
uncovered cellular mechanism may, in fact, include mitochondrial
SIRT3 (Di Sante et al., 2015). Strengthening this hypothesis, SIRT3-null
mice exposed to MPTP exhibited reduced SOD2 and glutathione per-
oxidase protein levels compared with wild-type animals (Liu et al.,
2015). Moreover, SIRT3 was previously found to act on PINK1 gene
expression and mitophagy via the activation of Forkhead box protein
O3 (FOXO3A) (Mei et al., 2009). The existence of a SIRT3-FOXO3A-
PINK1-Parkin axis was recently confirmed in mice (Yu et al., 2017).
Zhang and colleagues further studied the pathway, which is now also
thought to include PGC-1α and estrogen-related receptor alpha (ERRα).
The two proteins directly interact at the SIRT3 promoter regulating the
gene’s expression and SOD2 acetylation, which influences dopami-
nergic neuron survival (Zhang et al., 2016). Lysine 68 in SOD2 was
identified as the acetylation site for SIRT3 (Shi et al., 2017a). Ad-
ditionally introducing a knockout of the antioxidant protein DJ-1,
which can directly bind and activate SIRT1 (Takahashi-Niki et al.,
2016), further exacerbated the oxidative stress and neuronal degen-
eration phenotypes in SIRT3-null mice (Shi et al., 2017a). The effect of
SIRT3 on the viability of dopaminergic neurons has also been observed
in an adeno-associated virus-expressing mutant (A53 T) alpha-synuclein
rat model of Parkinsonism (Gleave et al., 2017).
With regard to endogenous PD models, Schwab and colleagues de-
termined the protein levels of SIRT1-3 in iPSC-derived neurons from
patients with the G2019S mutation in LRRK2. Western blotting analyses
revealed elevated levels of all three proteins. To test if this increase was
due to excessive kinase activity, the authors performed a rescue ex-
periment using the LRRK2 kinase inhibitor GSK2578215 A (Table 2).
However, while the treatment reduced mitochondrial velocity, it had no
effect on SIRT1, SIRT2, or SIRT3 expression levels or any other mi-
tochondrial function phenotypes observed in the cells (Schwab et al.,
2017). In conclusion, an age-associated decline in the capacity of sir-
tuins to act upon mitochondrial stress may also play a role in the do-
paminergic neuron loss in PD.
7.5. MicroRNA and mitochondrial anomalies in PD
With respect to mitochondrial function in PD, micro RNAs (miRNA)
are the most intensively studied small non-coding RNAs (which also
include Piwi-interacting RNAs and small nucleolar RNAs) (Leggio et al.,
2017). MiRNAs are typically 21–22 nt long and they modulate the ex-
pression of specific targets by interfering with mRNA. This interaction
destabilizes the mRNA or prevents its translation (Leggio et al., 2017).
MiRNA profiling in different post-mortem brain tissue from IPD patients
revealed widespread dysregulation, including expression changes in the
cingulate gyri, cerebellum, putamen, midbrain, SN, prefrontal and
frontal cortex, amygdala and striatum (Martinez and Peplow, 2017).
Some of these miRNAs specifically target PD genes that have been as-
sociated with mitochondrial function. MiR-7, which is highly abundant
in TH-positive nigral neurons (Choi et al., 2014), was found to interfere
with alpha-synuclein gene expression and to protect against oxidative
stress as early as in 2009 (Junn et al., 2009). Recent data in (MPP
+)-treated HEK293 cells underlined that miR-7, together with miR-
153, regulates the ROS-mediated de novo synthesis of alpha-synuclein
(Je and Kim, 2017). Reduced levels of miR-34b and miR-34c in human
brain samples correlated with lower abundances of the proteins DJ-1
and Parkin. SH-SY5Y cells depleted of miR-34b or miR-34c showed
reduced mitochondrial membrane potential, decreased ATP levels and
more fragmented mitochondria (Minones-Moyano et al., 2011). Ad-
ditionally, DJ-1 mRNA was identified as a direct target of miR-4639-5p
(Chen et al., 2017). With regard to PINK1, miR-27a and miR-27b were
demonstrated to supress the gene’s expression thereby inhibiting
clearance of damaged mitochondria (Kim et al., 2016). An inverse re-
lationship was also reported between miR-205 and LRRK2 protein ex-
pression. Induction of miR-205 in neurons overexpressing LRRK2
R1441 G sufficed to rescue a neurite outgrowth phenotype (Cho et al.,
2013). Evidence for a role of miRNAs in modulating mitochondrial-
lysosomal cross talk in PD comes from a 6-hydroxydopamine (6-OHDA)
stress model. Treatment of SH-SY5Y cells with the neurotoxin led to a
significant downregulation of miR-5701. Expression of a miR-5701
mimic caused a reduction in complex I activity, ATP and NADH levels.
Moreover, the levels of the autophagy marker LC3-II were increased in
the presence of miR-5701, whereas the turnover of p62 was decreased.
These results indicated that miR-5701 is crucial for mitochondrial en-
ergetics and the maturation of autophagolysosomes as well as lyso-
somal function (Prajapati et al., 2018). MiRNAs have potential as
therapeutic targets in PD warranting further studies into the cellular
pathways regulating gene expression.
8. Therapeutic approaches targeting mitochondria in PD
PD is a slowly progressive, disabling condition. There is a pressing
need to develop neuroprotective therapy to modify the natural history
of this disorder. Multiple strategies have been employed to address this
need, and many target mitochondrial function. Key studies involving
preclinical studies and clinical trials are outlined below.
8.1. Antioxidant therapies
There is a range of preclinical studies that suggest that antioxidants
may address mitochondrial dysfunction in PD. However, these pro-
mising investigations have not yet translated into a beneficial effect in
clinical trials.
Methylene blue (MB) is a renewable electron cycler in the mi-
tochondrial electron transport chain, with antioxidant and cell en-
ergetic enhancing properties (Biju et al., 2018). Investigators have used
acute toxin models of PD to demonstrate that MB has beneficial effects
on nigrostriatal dopaminergic cell loss and motor impairment (Rojas
et al., 2009; Smith et al., 2017; Wen et al., 2011). In a chronic MPTP/
probenecid mouse model it was shown that olfactory dysfunction
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improved with MB treatment, in comparison to currently available anti-
parkinsonian medication, which had no benefit (Biju et al., 2018).
These results indicate that MB is a promising neuroprotective agent
with potential beneficial effects for, both, motor and non-motor mani-
festations of PD (Biju et al., 2018).
There is evidence that the mitochondrially targeted antioxidant,
mito-apocynin (Mito-Apo), has neuroprotective effects on pre-clinical
PD (Ghosh et al., 2016; Langley et al., 2017). In a recent study, mi-
tochondrial transcription factor A was selectively knocked out to create
MitoPark mice, an animal model of PD (Langley et al., 2017). It was
shown that Mito-Apo attenuated severe nigrostriatal degeneration,
improved mitochondrial function, and inhibited NOX2 activation, oxi-
dative damage and neuroinflammation (Langley et al., 2017). These
results support a clinical application of a Mito-Apo as neuroprotective
and anti-neuroinflammatory agent in PD therapy (Langley et al., 2017).
The monoamine oxidase-B (MAO-B) inhibitor, N-Methyl, N-pro-
pynyl-2-phenylethylamine (MPPE), is a selegeline analogue, and has
been shown to attenuate dopaminergic damage induced by MPTP (Shin
et al., 2016). The effect of MPPE depends on inhibition of mitochondrial
oxidative stress, mitochondrial translocation of p53, and pro-apoptotic
change (Shin et al., 2016). The Deprenyl and Tocopherol Antioxidative
Therapy of Parkinsonism (DATATOP) Trial suggested that deprenyl
(selegeline), but not tocopherol, delayed the onset of disability in early,
untreated PD (Parkinson Study Group, 1993). However, it was unclear
whether this was a symptomatic effect or a slowing of the underlying
disease process (Parkinson Study Group, 1993). A trial of a newer MAO-
B inhibitor, rasagaline, showed a benefit consistent with a disease
modifying effect with a dose of 1mg, but not with a higher dose of 2mg
(Olanow et al., 2009). Given these mixed results, no definitive re-
commendations regarding rasagaline can be made (Mehta et al., 2010).
Pramipexole exists in two isomers, the S(−) enantiomer, which is a
potent D3/D2 receptor agonist used extensively in the management of
PD, and the R(+) enantiomer, which has little dopamine agonist effects
(Ferrari-Toninelli et al., 2010). Using differentiated SH-SY5Y neuro-
blastoma cells, investigators showed that, both, S(−) and R(+) pra-
mipexole have equipotent effects of preventing cell death induced by
H2O2 and inhibiting mitochondrial reactive oxygen species generation
(Ferrari-Toninelli et al., 2010). This suggests that pramipexole has an
anti-oxidant and neuroprotective activity, which is independent of its
role as a dopamine receptor agonist.
It has been reported that MitoQ, a mitochondrial targeted anti-
oxidant, can protect dopaminergic neurons in a 6-OHDA-induced model
of PD (Xi et al., 2018). The mechanism involves activation of PGC-1α to
augment Mfn2-dependent mitochondrial fusion (Xi et al., 2018). A
double-blind, placebo-controlled study assessed MitoQ as a potential
therapy for disease modification in PD patients (Snow et al., 2010).
Unfortunately, this study showed no benefit of MitoQ for disease pro-
gression (Snow et al., 2010).
Coenzyme Q10 (CoQ10) is an antioxidant that supports the function
of mitochondria. The effect of CoQ10 on disease progression was in-
vestigated in a large phase III randomized, placebo-controlled, double-
blind clinical trial with a change in total unified Parkinson's disease
rating scale (UPDRS) score (Parts I-III) as the primary outcome measure
(Parkinson Study Group QE3 Investigators et al., 2014a). While Coen-
zyme Q10 was safe and well tolerated, the study showed no evidence of
clinical benefit.
A triple-blinded, randomised, placebo-controlled trial to investigate
the efficacy and safety of ViNeuro in PD has been completed
(NCT00517842), but the results are currently not available. The action
of ViNeuro includes a mitochondrial antioxidant effect.
The drug EPI-589, which modifies cellular GSH levels and has an
antioxidant effect, was developed to treat mitochondrial disease in
children. It is currently the subject of a phase 2 study (NCT02462603)
with primary outcome being safety and secondary outcomes of clinical
and biomarker parameters.
N-acetylcysteine (NAC), a GSH precursor, is currently used to treat
acetaminophen overdose and for its mucolytic properties in cystic fi-
brosis (Ammal Kaidery and Thomas, 2018). NAC has antioxidant
properties by fortifying GSH and has also shown benefits in preclinical
models of PD (Ammal Kaidery and Thomas, 2018; Berman et al., 2011;
Clark et al., 2010; Martinez Banaclocha, 2000; Rahimmi et al., 2015). A
cell line study of NAC showed an increase in midbrain dopaminergic
neurons surviving after exposure to rotenone in comparison to no NAC
(Monti et al., 2016). This was combined with a preliminary clinical
study, which showed significantly increased DAT binding in the cau-
date and putamen on DaTscan and improved UPDRS scores in the NAC
group (Monti et al., 2016). This study suggests that a large-scale clinical
trial is necessary to investigate the therapeutic effect of NAC for PD.
The ability to selectively induce a range of cytoprotective and an-
tioxidative enzymes under the control of a single transcription factor
such as Nrf2 is a promising strategy (Ammal Kaidery and Thomas,
2018). Compounds including synthetic triterpenoids and fumaric acid
esters can activate the Nrf2 pathway and have a neuroprotective effect
in animal models of PD (Ahuja et al., 2016; Ammal Kaidery and
Thomas, 2018; Kaidery et al., 2013; Lastres-Becker et al., 2016). A drug
used to treat multiple sclerosis, Tecfidera, has been repurposed to ex-
plore its potential to treat PD (Lastres-Becker et al., 2016). Tecfidera is a
putative Nrf2 activator and is the oral formulation of dimethylfumarate
(DMF) (Ahuja et al., 2016). Ahuja and colleagues compared the effects
of DMF and its metabolite monomethylfumarate (MMF) on Nrf2 sig-
nalling and ability to block MPTP-induced experimental PD (Ahuja
et al., 2016). Both DMF and MMF were neuroprotective against MPTP
neurotoxicity through Nrf2-mediated antioxidant, anti-inflammatory,
and mitochondrial functional/biogenetic effects, but MMF does so
without depleting GSH and inhibiting mitochondrial and glycolytic
functions. The results suggest that MMF, rather than DMF, is a pro-
mising therapeutic intervention in PD while keeping side effects to a
minimum.
Uric acid is an antioxidant, which has neuroprotective effects in
preclinical models by activating the Nrf2 pathway (Ammal Kaidery and
Thomas, 2018; Zhang et al., 2014). Further evidence of the relationship
between uric acid and PD include the finding that there is a decreased
incidence of PD in individuals with higher serum urate levels/gout
(Cortese et al., 2018; Davis et al., 1996; Weisskopf et al., 2007). While a
diet rich in urate could be neuroprotective in PD, this has to be ba-
lanced by the expected adverse effects including gout and cardiovas-
cular disease (Ammal Kaidery and Thomas, 2018). The Safety of Urate
Elevation in PD (SURE-PD) demonstrated that the urate precursor in-
osine was safe, well tolerated and effective at raising urate levels in
early PD (Parkinson Study Group SURE-PD Investigators et al., 2014b).
Currently, a phase 3 clinical trial (SURE-PD3 trial; NCT02642393) is
underway to determine whether oral inosine can slow clinical pro-
gression in early PD (Crotty et al., 2017).
8.2. Creatine supplementation
Creatine is a natural compound, which plays a critical role in cel-
lular energy homeostasis (Mo et al., 2017). Oral creatine supple-
mentation has been shown to have a protective effect on MPTP mouse
models (Klivenyi et al., 2003; Matthews et al., 1999). However, for
patients with early and treated PD, creatine monohydrate therapy did
not result in an improvement in clinical outcomes (Writing Group for
the NINDS Exploratory Trials in Parkinson Disease (NET-PD)
Investigators et al., 2015). A recent meta-analysis of five randomized
control trials showed no observed benefit of creatine in PD (Mo et al.,
2017).
8.3. Ursodeoxycholic acid treatment
Ursodeoxycholic acid (UDCA) is used for the treatment of primary
biliary cirrhosis, but preclinical studies have shown a protective effect
for, both, toxic-induced and genetic forms of PD by improving
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mitochondrial function (Abdelkader et al., 2016; Ammal Kaidery and
Thomas, 2018; Mortiboys et al., 2015). A phase 1 trial is currently
underway measuring plasma UDCA before and after oral UDCA dosing,
as well as the effects of oral UDCA on brain bioenergetics derived from
magnetic resonance spectroscopy measurements (NCT02967250).
8.4. Modifying the interaction with alpha-synuclein
Alpha-synuclein is a major target for the development of novel
therapies in PD. This would be expected to influence mitochondrial
function, given the reciprocal interaction between alpha-synuclein ag-
gregation and mitochondrial impairment as described in Section 4.
Alpha-synuclein antibodies may have a therapeutic effect by en-
hancing clearance, reducing cellular toxicity and spread of pathology
(Lang and Espay, 2018). Monoclonal antibodies to different parts of
alpha-synuclein have shown promise in preclinical trials paving the
way for phase 2 randomised control trials (the PASADENA trial;
RO7046015, the SPARK trial; BIIB054) (Lang and Espay, 2018).
A recent study used aptamers to reduce alpha-synuclein aggregation
in vitro and in cells and to induce alpha-synuclein degradation via the
lysosomal pathway (Zheng et al., 2018). These effects were able to
rescue mitochondrial dysfunction due to alpha-synuclein over-
expression.
Decreased levels of the master regulator of mitochondrial biogen-
esis, PGC-1α, may also indirectly induce alpha-synuclein toxicity and
mitochondrial dysfunction. For example, down-regulation of PGC-1α in
PGC-1α reference gene (RG-PGC-1α)-deficient mice induces alpha-sy-
nuclein oligomerization and toxicity (Eschbach et al., 2015). Ad-
ditionally, pharmacological activation or genetic overexpression of RG-
PGC-1α lowers alpha-synuclein oligomerization and rescues alpha-sy-
nuclein-mediated toxicity (Eschbach et al., 2015). This is in keeping
with the concept that PGC-1α downregulation and alpha-synuclein
oligomerization can form a ‘vicious circle’. This suggests that restora-
tion of PGC-1α could be a therapeutic strategy for PD (Eschbach et al.,
2015).
8.5. Enhancement of mitophagy
Mitophagy is thought to be impaired in PD as outlined previously
(Section 5). Enhancement of mitophagy is therefore an appealing
strategy for the treatment of PD. However, this strategy is limited by the
lack of pharmacological agents that selectively enhance mitophagy
(Moors et al., 2017). Compounds that are used to trigger mitophagy in
vitro, such as trifluorocarbonylcyanide phenylhydrazone and antimycin/
oligomycin combinations, are toxic, non-specific, and trigger non-phy-
siological levels of mitophagy, and so they are not considered suitable to
be used for therapeutic applications (East and Campanella, 2016; Moors
et al., 2017). The p62-mediated mitophagy inducer is thought to enhance
mitophagy but has not been applied to preclinical PD models (Moors
et al., 2017). Other options for enhancing mitophagy include induction
of alternative mitophagy pathways (Koentjoro et al., 2017) or specific
gene therapy approaches as outlined below (Section 8.11).
8.6. Modulating calcium homeostasis
The dihydropyridine calcium channel antagonist, isradipine, has
been demonstrated to be neuroprotective in animal models of PD (Ilijic
et al., 2011). A recent study administered the Cav1 channel inhibitor
isradipine to mice to assess for benefit of SN dopaminergic neurons
(Guzman et al., 2018). This treatment reduced cytosolic Ca2+ oscilla-
tions in nigral dopaminergic neurons without changing autonomous
spiking or expression of Ca2+ channels. The effect was mimicked by
knocking down expression of Cav1.3 channel subunits. Moreover, the
treatment led to lower mitochondrial oxidant stress, a reduction of a
high basal rate of mitophagy, and normalized mitochondrial mass. This
demonstrated that Cav1 channels increase mitochondrial oxidant stress
and turnover in vivo. Therefore, chronic isradipine treatment re-
modelled SN dopaminergic neurons in a manner that protected against
mitochondrial challenges and autophagic stress. A Phase II safety, tol-
erability, and dose selection study of isradipine has been completed
(Parkinson Study Group, 2013), and a phase III clinical trial for early
PD is underway (NCT02168842).
8.7. Neuroprotection from hormones involved in glucose metabolism
Hormones involved in glucose metabolism such as ghrelin and
glucagon-like-peptide-1 (GLP-1) may also modulate mitochondrial
function (Wilkins and Morris, 2017). For example, ghrelin has been
shown to be protective against rotenone and MPTP in preclinical
models (Wilkins and Morris, 2017). A novel GLP-1/GIP dual agonist
(DA-JC1) had a neuroprotective effect in a MPTP mouse model and
enhanced levels of the neuroprotective brain-derived neurotropic factor
(BDNF) (Ji et al., 2016).
Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, was
investigated in a single-centre, randomised, double-blind, placebo-
controlled trial, in patients with moderate PD (Athauda et al., 2017).
Exenatide showed beneficial effects on off-medication motor scores in
PD beyond the period of exposure to the drug. However, it is unclear
whether this result was due to modification of the underlying disease
process, or a long-lasting symptomatic effect (Ammal Kaidery and
Thomas, 2018).
8.8. Proliferator-activated receptor gamma agonists
The thiazolidinediones, including rosiglitazone and pioglitazone,
activate proliferator-activated receptor gamma (PPAR-γ) and are used
to treat type 2 diabetes mellitus but have also shown promise in treating
PD (Wilkins and Morris, 2017). There is evidence that the PPAR-γ
agonists protect mitochondrial membrane potential and prevent apop-
tosis (Wu et al., 2009). Pioglitazone and rosiglitazone have been shown
to be neuroprotective in preclinical models of PD (Barbiero et al., 2014;
Carta et al., 2011; Schintu et al., 2009; Wilkins and Morris, 2017).
However, a clinical study of early PD did not show any benefit from
pioglitazone in terms of disease progression or biomarker levels (NINDS
Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE
Investigators, 2015; Simon et al., 2015; Wilkins and Morris, 2017).
8.9. Mitochondrial replacement
Replacement of dysfunctional mitochondria with functional exo-
genous mitochondria is an innovative strategy for treating PD. In an
experimental PD mouse model induced by MPTP, mitochondrial re-
placement halted PD progress by increasing ATP production, reducing
reactive oxygen species, and preventing cell apoptosis and necrosis (Shi
et al., 2017b).
8.10. Exercise
Preclinical models of PD suggest that exercise could be neuropro-
tective (Wilkins and Morris, 2017). A recent study showed that tread-
mill exercise improved gait speed and balance, decreased oxidative
stress, improved mitochondrial fusion and fission, increased mi-
tochondrial amounts, and possibly attenuated dopaminergic neuron
degeneration in a unilateral 6-OHDA rat model of PD (Chuang et al.,
2017).
A number of studies have evaluated the benefit of exercise in PD
(Wilkins and Morris, 2017). A systematic review and meta-analysis of
randomized controlled trials found strong evidence that resistance
training can improve muscle strength in PD and that endurance training
can improve cardio-respiratory fitness in PD (Uhrbrand et al., 2015).
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8.11. Gene therapy
Genes involved in recessive forms of PD, such as Parkin and PINK1,
may be particularly amenable to treatment with gene therapy, since
loss of function mutations may be rescued by the overexpression of
functional protein (Valdes and Schneider, 2016). However, individuals
with Parkin mutations have atypical forms of PD with slow progression
and early onset and, in the majority of cases, there is absence of typical
alpha-synuclein-containing Lewy bodies in the SN (Bruggemann and
Klein, 1993; Valdes and Schneider, 2016). It is not clear, if enhancing
the Parkin-PINK1 pathway will be beneficial in idiopathic PD. In fact,
there may be adverse effects given that overexpression of both mutant
and wildtype Parkin has been show to induce dopaminergic cell death
(Valdes and Schneider, 2016; Van Rompuy et al., 2014).
A recent study suggested that induction of NIX can restore mito-
phagy in PINK1- and Parkin-related PD patient cell lines (Koentjoro
et al., 2017). Furthermore, overexpression of NIX can improve mi-
tochondrial ATP production in patient cells (Koentjoro et al., 2017).
These findings suggest that NIX may also be a target for gene therapy.
9. Summary and future perspectives
Within the framework of this article, we have reviewed studies on
mitochondria and PD published in the last three decades. Recent devel-
opments have added to a large body of evidence supporting the role of
mitochondrial dysfunction in the pathophysiology of both familial and
sporadic forms of PD. The current research suggests that this role is
complex and multifaceted, with an interplay of elements involving the
mitochondrial respiratory chain, mitochondrial genome, interactions
with alpha-synuclein, mitophagy/mitochondrial homeostasis, mi-
tochondrial vesicular trafficking and newly emerging mechanisms such
as a role for inflammation. The molecular pathways involved appear to
overlap at multiple points. The next challenge will be to better char-
acterize these molecular interactions as they may emerge as targets for
PD therapy across different subtypes of the disease. For such approaches
to be successful, movement away from studies using isolated cell types
and towards those assessing PD neurons against the backdrop of their
supporting tissue should be made. IPSC technology holds the key for the
development of two or three dimensional co-culture systems. When
preparing this synopsis, a particular focus was placed on mitochondrial
phenotyping in iPSC-derived PD models. This analysis revealed that the
potential of iPSC technology to investigate the mitochondrial component
in idiopathic and very rare PD types such as DJ-1, ATP13A2- or VPS35-
associated PD has successfully identified important contributions to
biologically relevant pathogenic disease mechanisms but has not been
fully exploited. For the genetic forms of PD, this is most likely explained
by the limited number of patient iPSC cultures currently available
worldwide. Regarding IPD, the phenotypic heterogeneity of sporadic
cases still represents a significant challenge in PD research as it impedes
the identification of disease mechanisms. However, by applying high-
throughput omics methods to stratified endogenous neuronal cell models
(which recapitulate the exact genotype underlying the disease in a spe-
cific IPD patient) this obstacle may be overcome in the near future.
Moreover, protocols for the culture of multicellular PD models, such as
midbrain organoids, have only recently been published and are not yet
widely used in the PD field (Monzel et al., 2017). Studies in co-culture
systems will help understand how mitochondrial dysfunction in neurons
and glia cells mutually influence each other.
Targeting mitochondrial defects may open new avenues for the
development of PD therapies. This concept is supported by numerous
preclinical studies. However, multiple drug trials targeting mitochon-
drial impairment have failed to show benefit, particularly those em-
ploying antioxidant therapies. The lack of success in clinical trials can
be attributed to an incomplete understanding of the molecular path-
ways and targets, heterogeneity of the patient population, and the lack
of adequate biomarkers to monitor drug efficacy (Lang and Espay,
2018). Even if a clinical trial purports to show a benefit, there are
difficulties in distinguishing the disease-modifying effect from a
symptomatic improvement (Mehta et al., 2010). Therapies could be
developed to specifically target the pathways known to be involved,
such as mitophagy, mitochondrial biogenesis, fusion/fission and traf-
ficking. Larger clinical trials with more uniform sample populations will
be useful. Highly specific and sensitive disease biomarkers would allow
detecting even subtle improvements due to novel drug therapies. There
are reasons for optimism with a recent study of exenatide showing
benefit (Ammal Kaidery and Thomas, 2018; Athauda et al., 2017) and
several large clinical trials underway. Given that loss of function mu-
tations in Parkin and PINK1 can cause PD, this may be rescued by the
overexpression of functional mitophagic proteins, opening up gene
therapy as another potential avenue for treatment (Koentjoro et al.,
2017; Valdes and Schneider, 2016).
New research is emerging at a rapid pace, providing further insights
into mitochondrial dysfunction in PD. Despite this progress, there is still
much to learn about the precise disease mechanisms involved.
Mitochondrial dysfunction clearly plays a fundamental role in PD and
should be a key theme for future research.
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